Radiation safety considerations for post-iodine-131 thyroid cancer therapy

Area of Science:

• Nuclear medicine
• Radiological health
• Oncology

Background:

• Radioactive iodine (131I) therapy is a standard treatment for thyroid cancer.
• Determining safe patient release criteria is crucial for public health.
• Existing guidelines may not be specific enough for 131I-treated thyroid cancer patients.

Purpose of the Study:

• To develop evidence-based guidelines for resuming close personal contact after 131I therapy.
• To establish safe post-discharge intervals for thyroid cancer patients.

Main Methods:

• External exposure rates were measured in 27 thyroid cancer patients post-hospital discharge.
• Measurements were taken using a calibrated ionization survey meter at varying distances (0.3, 0.6, 1 meter).
• Exposure rates were recorded 2-7 days after release, with maximum readings obtained via vertical instrument movement.

Main Results:

• All patients exhibited exposure rates below 2 mR/hr at 1 meter within 2-4 days post-discharge.
• 88% of patients (21/24) had exposure rates below 2 mR/hr at 0.6 meters within 2-4 days.
• These findings indicate a rapid decrease in external radiation levels.

Conclusions:

• Direct patient measurements support the development of specific guidelines for 131I-treated thyroid cancer patients.
• Guidelines can be established to ensure patient safety and align with radiologic health standards.
• Safe personal contact can be resumed relatively quickly after hospital release based on measured exposure rates.